SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Telegram Restored on Apple App Store After Temporary Removal 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
SEATTLE, April 09, 2018 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2018 financial results after the close of trading on Tuesday, May 8, 2018. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID: 6188428. To listen to a live webcast, please visit the investor relations section of the company’s website at nanostring.com.
A replay of the call will be available beginning May 8, 2018 at 7:30pm ET through midnight on May 15, 2018. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 6188428. The webcast will also be available on the Company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,900 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. For more information, please visit www.nanostring.com.
Contact:
Doug Farrell
Vice President, Investor Relations & Corporate Communications
[email protected]
Phone: 206-602-1768
